Future research should prioritize the optimization of predictive biomarkers through the development of circulating tumor DNA (ctDNA)-based strategies for monitoring molecular response, as well as the relative abundance and activity of tumor cells in CLDN18.2-positive gastric cancer. This evidence concerns the gene CLDN18 and neoplasm.